NLRP3 and metabolic dysfunction-associated steatotic liver disease: Clinical experiments have shown that the activation of the NLRP3 inflammasome is highly increased in NAFLD patients, and anthocyanins can significantly reduce NLRP3 inflammasome components such as caspase-1, IL-1β, and IL-18, providing a basis for the development of anti-inflammatory therapy for NAFLD [71].